Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Skye Bioscience, Inc. Common Stock(SKYE)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for SKYE
11/05/2026: SKYE (1-star) is currently NOT-A-BUY. Pass it for now.
Skye Bioscience is a clinical-stage biotechnology company focused on developing novel therapeutics for metabolic diseases, specifically targeting the endocannabinoid system. Its primary strength lies in the development of nimacimab, a proprietary CB1 inhibitor aimed at the lucrative obesity market. The company's investment story hinges on successful clinical trial milestones that could validate its non-GLP-1 mechanism. However, Skye faces significant risks, including the absence of commercial revenue, high development costs, and intense competition from established pharmaceutical giants. This stock may suit speculative, growth-oriented investors with a high risk tolerance who are looking for exposure to potential breakthroughs in metabolic health.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company offers high growth potential contingent on clinical success, but lacks the established revenue of typical growth holdings. |
| Momentum investor | Strong fit while signal remains positive | Clinical trial milestones often drive significant short-term price momentum. |
| Value investor | Weak fit | The company lacks earnings, book value, or cash flow to support a traditional value assessment. |
| Dividend investor | Weak fit | There is no dividend income and the company requires capital preservation. |
| Low-risk investor | Weak fit | The extreme volatility and binary nature of clinical outcomes make this unsuitable for low-risk portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Clinical-stage stocks frequently experience sharp, news-driven price swings. |
| Valuation risk | High | Valuations are speculative and highly sensitive to clinical success probabilities. |
| Competition risk (Obesity/Metabolic) | High | Well-capitalized giants like Lilly and Novo Nordisk hold dominant positions. |
| Business quality | Medium | The company is in an early development phase without an established product franchise. |
| Dividend income | Low / none | Income generation is not part of the business model. |
| Execution risk | High | Clinical trial success is uncertain and essential for company survival. |
Price Behavior
Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.
Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit 24.83% | Avg. Invested days 18 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 11/05/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 5.05M USD | Price to earnings Ratio - | 1Y Target Price 68 |
Price to earnings Ratio - | 1Y Target Price 68 | ||
Volume (30-day avg) 29.2K shares | Beta 3.15 | 52 Weeks Range 0.26 - 2.25 | Updated Date 11/05/2026 |
52 Weeks Range 0.26 - 2.25 | Updated Date 11/05/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -10.16 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Clinical Development | Research and development of cannabinoid-based drugs like nimacimab. | The company does not currently sell products and earns no revenue; investors are betting on future clinical success. |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -4.44M | Price to Sales(TTM) 117.9 |
Enterprise Value -4.44M | Price to Sales(TTM) 117.9 | ||
Enterprise Value to Revenue 220.74 | Enterprise Value to EBITDA -2.56 | Shares Outstanding 4.43M | Shares Floating 2.99M |
Shares Outstanding 4.43M | Shares Floating 2.99M | ||
Percent Insiders 4.24 | Percent Institutions 46.05 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.